Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder
PurposeFingolimod, an oral treatment for relapsing-remitting multiple sclerosis (RRMS), has been associated with a significant rebound in disease activity after therapy cessation. We described a patient with neuromyelitis optica spectrum disorder (NMOSD) who was previously diagnosed with RRMS and ex...
Main Authors: | Wei Lin, Chung-Hsing Chou, Fu-Chi Yang, Chia-Kuang Tsai, Yu-Kai Lin, Yueh-Feng Sung |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-04-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1115120/full |
Similar Items
-
Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations
by: Brian Barry, et al.
Published: (2019-11-01) -
Comparing the Efficacy of Monthly Cyclophosphamide as Monotherapy versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis
by: Vahid Shaygannezhad, et al.
Published: (2017-08-01) -
A Validated HPLC-MS/MS Method for Quantification of Fingolimod and Fingolimod-Phosphate in Human Plasma: Application to Patients with Relapsing–Remitting Multiple Sclerosis
by: Claudia Fracasso, et al.
Published: (2022-06-01) -
Sensory-Neural Hearing Loss as an Early Rebound Relapse after Fingolimod Cessation in Multiple Sclerosis
by: Abdoreza Naser Moghadasi, et al.
Published: (2020-07-01) -
Case Report: Persisting Lymphopenia During Neuropsychiatric Tumefactive Multiple Sclerosis Rebound Upon Fingolimod Withdrawal
by: Valeria Koska, et al.
Published: (2021-10-01)